Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients

NCT07715929 · Not yet recruiting

Last updated 2026-07-27

This clinical trial is testing whether the medication tirzepatide can help prevent the return of an irregular heartbeat in people with obesity who have undergone a procedure called catheter ablation.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 710 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2026-09 · est. completion 2029-12

What this study is testing ClinicalTrials.gov NCT07715929 ↗

Description as written by the study sponsor.

Obese patients with atrial fibrillation (AF) have a high recurrence rate after catheter ablation, even at experienced centers. Weight reduction improves post-ablation outcomes, but lifestyle measures alone are difficult to sustain. Tirzepatide, a once-weekly GIP/GLP-1 dual receptor agonist, produces greater weight loss than GLP-1 monotherapy and may confer additional cardiometabolic benefits. This multicenter, randomized, open-label, parallel-group, superiority trial evaluates whether adding standardized tirzepatide treatment to a structured lifestyle intervention - compared with the lifestyle intervention alone - reduces AF recurrence within 1 year after ablation in obese patients.

Treatments tested

Tirzepatide also known as Mounjaro Drug

Dual GIP and GLP-1 receptor agonist administered as a weekly subcutaneous injection. Titrated from 2.5 mg/week to a target of 10 mg/week over 12 weeks, then maintained at the maximum tolerated dose for the remainder of the 52-week treatment period.
Structured Lifestyle Intervention Behavioral

Guideline-directed AF management (rate/rhythm control, anticoagulation by CHA2DS2-VASc). Structured lifestyle intervention: 500 kcal/day caloric deficit; exercise prescription of ≥150 min/week moderate aerobic; smoking cessation and alcohol moderation counseling.

Main thing measured	Number of Participants With Recurrence of Atrial Fibrillation, Atrial Flutter, or Atrial Tachycardia
Sponsor	Yunlong Wang
Conditions studied	Atrial Fibrillation, Obesity & Overweight, Catheter Ablation
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07715929 ↗